Contributors to this release include: ITTM, U Luxembourg, Erasmas Medical Center, Imperial College of London, J&J, Pfizer, Clarivate Analytics (formerly Thomson Reuters), U Liverpool, eTRIKS, TraIT, and the Hyve.
Harvard Business School (HBS) announced on the 20th of May 2016, that Dana-Farber’s MatchMiner has been named the winner of the Precision Trials Challenge.
A joint developmental effort between Dana-Farber’s KSG group, located in Boston, headed by Ethan Cerami PhD, and The Hyve, also located in Boston, has resulted in the inception of MatchMiner, an open computational platform for matching patient-specific genomic profiles to precision cancer medicine clinical trials.
Notable improvements include:
- A completely rewritten procedure for installation of the current version of the tranSMART Platform. Feedback at the Annual Meeting indicated that this was a major barrier to wider adoption and use of the system
- An updated development roadmap through 2017
- A single site to explore data available to the tranSMART community with additional public data sets that are available for loading into your own tranSMART database
- A new location for Use Cases from users of the Platform
- And many updated and new sections!